Experimental CAR-T therapy takes aim at Hard-to-Treat lupus kidney disease
NCT ID NCT07364396
First seen Jan 29, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the disease. About 39 adults who have not responded to standard treatments will receive a single infusion of CRC01 and be monitored for safety and kidney improvement over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CRC01 (a CAR-T cell therapy made from the patient's own immune cells, modified to target and destroy certain immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with severe lupus nephritis that hasn't responded to other therapies.
What could go wrong
This is an early-phase trial with only 39 participants, so results may not apply to everyone. There are known risks like cytokine release syndrome and neurotoxicity, and the therapy may not work for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.